Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies
Inka Albrecht, … , Olle Kämpe, Ingrid E. Lundberg
Inka Albrecht, … , Olle Kämpe, Ingrid E. Lundberg
Published November 9, 2015
Citation Information: J Clin Invest. 2015;125(12):4612-4624. https://doi.org/10.1172/JCI81031.
View: Text | PDF
Research Article Immunology

Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies

  • Text
  • PDF
Abstract

Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1–negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.

Authors

Inka Albrecht, Cecilia Wick, Åsa Hallgren, Anna Tjärnlund, Kanneboyina Nagaraju, Felipe Andrade, Kathryn Thompson, William Coley, Aditi Phadke, Lina-Marcela Diaz-Gallo, Matteo Bottai, Inger Nennesmo, Karine Chemin, Jessica Herrath, Karin Johansson, Anders Wikberg, A. Jimmy Ytterberg, Roman A. Zubarev, Olof Danielsson, Olga Krystufkova, Jiri Vencovsky, Nils Landegren, Marie Wahren-Herlenius, Leonid Padyukov, Olle Kämpe, Ingrid E. Lundberg

×

Figure 1

IIM patients have anti-FHL1 autoantibodies that are specific to this disease.

Options: View larger image (or click on image) Download as PowerPoint
IIM patients have anti-FHL1 autoantibodies that are specific to this dis...
(A) Sera from patients with IIM (PM, DM, or IBM; n = 141) were analyzed by ELISA for reactivity to recombinant FHL1-MaBP fusion protein and compared with sera from sex- and age-matched HCs (n = 126). (B) A cutoff value was calculated, allowing subdivision of the patients into anti-FHL1– (aFHL1–) and anti-FHL1+ patients (cutoff = mean [norm. absorbance HC] + 2 × SD = 0.26228). (C) Anti-FHL1 positivity was confirmed by another ELISA using recombinant His-tagged FHL1 and by comparing anti-FHL1+ (n = 35) with sex- and age-matched anti-FHL1– patients (n = 30) as well as by Western blotting (D) using recombinant FHL1-MaBP fusion protein. All 35 of the anti-FHL1+ patients were analyzed (lanes 1–35). Lanes show reactivity of sera from anti-FHL1+ patients 10 and 29 to MaBP loaded next to FHL1-MaBP, of sera from 4 HCs (sera 3* with positive reactivity detected by ELISA in B), of sera from a positive control (PC) using a commercial anti-FHL1 antibody, and of sera from 3 anti-FHL1– patients. (E) Reactivity to FHL1 in sera from HCs and IIM patients was compared by ELISA with anti-FHL1 reactivity in sera from patients with MCTD (n = 19), RA (n = 67), pSS (n = 35), SLE (n = 33), and SSc (n = 32), as well as in sera from patients with neuromuscular disease (NMD; n = 9). Statistical analysis for A–C was performed using a 2-tailed Mann Whitney U test; each data point represents 1 individual, and horizontal bars indicate the mean values. For A, B, and E, normalized A405 values (norm. A405 = FHL1-MaBP-A405 minus MaBP-A405) are shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts